TapImmune, Inc. has signed a license agreement with Crucell N.V. Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited for the development and large-scale manufacturing of a multitude of biopharmaceuticals. In the use of recombinant vaccines using adenoviral vectors, PER.C6(R) cells do not generate replication competent adenoviruses, making it the state-of-the-art platform for the large-scale production of adenoviral vectors for clinical applications. The PER.C6(R) cell line is the best documented cell line for vaccine development to date. Its extensive Biologics Master File at the U.S. FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process. The partnership between TapImmune and Crucell is important for the production of TapImmune's vaccine products. Under the terms of this agreement, Crucell has the rights to negotiate a license for TapImmune's TAP technologies for infectious disease indications.

Calmune Corporation announced that it has established an exclusive research collaboration with Crucell N.V. focusing on research development, production and marketing of vaccines, proteins and antibodies that prevent and/or treat infectious diseases. Financial details of the agreement were not disclosed. Under this collaboration, Calmune will use SEBVI(TM), a proprietary technology to prepare a panel of potent, high-affinity human monoclonal antibodies (hMabs) against a pre-defined, undisclosed infectious disease target. Crucell will have the option to exclusively license these hMabs for further evaluation as development candidates, and to develop any that meet its required profile. Calmune will receive payments from Crucell at different stages of the discovery and development process, as well as a royalty on sales of products that incorporate antibodies generated by Calmune. By exploiting the power of the human immune response, Calmune's SEBVI(TM) technology allows natural, high-affinity, fully human antibodies against microbial targets to be efficiently recovered from Epstein Barr virus-transformed memory B cells.

Crucell NV reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company reported total revenues and other operating income increased by 15% to EUR 94.3 million, compared to EUR 82.1 million in the same quarter of 2008. The increase was driven by a robust 28% growth in product sales and in particular growth of paediatric and respiratory vaccines. Net cash from operating activities improved significantly to EUR 72.1 million, up from minus EUR 9.9 million in the same quarter of 2008. This was driven by the upfront payment of JNJ for participation in company's development programs. Operating profit was EUR 15.5 million compared to EUR 9.6 million operating profit in the same quarter of 2008. Operating profit was positively affected by a EUR 8.1 million impairment reversal of two state-of-the-art buildings in Bern (Switzerland). Net income was EUR 10.0 million compared to net income of EUR 12.8 million in the same quarter of 2008. Net result per share is EUR 0.15, compared to a net result per share of EUR 0.19 in the third quarter of 2008. For the nine months, the company reported net profit of EUR 8.4 million or EUR 0.13 per basic share on total revenues and other operating income of EUR 246.7 million compared to net loss of EUR 3.1 million or EUR 0.05 per basic share on total revenues and other operating income of EUR 189.6 million for the same period a year ago. Operating profit was EUR 21.0 million compared to operating loss of EUR 2.5 million for the same period a year ago. The company reiterated its combined full-year 2009 total revenues and other operating income to grow 20% in constant currencies. Operating profit for 2009 is expected to improve significantly compared to 2008. The company reported EUR 8.1 million impairment reversal of two buildings in Bern (Switzerland).